| Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours DM Berman, SS Karhadkar, A Maitra, R Montes de Oca, MR Gerstenblith, ... Nature 425 (6960), 846-851, 2003 | 1653 | 2003 |
| SUMOylation promotes de novo targeting of HP1α to pericentric heterochromatin C Maison, D Bailly, D Roche, RM de Oca, AV Probst, I Vassias, F Dingli, ... Nature genetics 43 (3), 220-227, 2011 | 253 | 2011 |
| A novel diagnostic screen for defects in the Fanconi anemia pathway A Shimamura, RM de Oca, JL Svenson, N Haining, LA Moreau, ... Blood, The Journal of the American Society of Hematology 100 (13), 4649-4654, 2002 | 170 | 2002 |
| Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing SV Gerhart, WA Kellner, C Thompson, MB Pappalardi, XP Zhang, ... Scientific reports 8 (1), 9711, 2018 | 166 | 2018 |
| Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin R Montes de Oca, PR Andreassen, SP Margossian, RC Gregory, ... Blood 105 (3), 1003-1009, 2005 | 157 | 2005 |
| Targeted disruption of the murine Fanconi anemia gene,Fancg/Xrcc9 Y Yang, Y Kuang, RM De Oca, T Hays, L Moreau, N Lu, B Seed, ... Blood, The Journal of the American Society of Hematology 98 (12), 3435-3440, 2001 | 150 | 2001 |
| Binding of barrier to autointegration factor (BAF) to histone H3 and selected linker histones including H1. 1 RM De Oca, KK Lee, KL Wilson Journal of Biological Chemistry 280 (51), 42252-42262, 2005 | 132 | 2005 |
| Barrier-to-autointegration factor proteome reveals chromatin-regulatory partners R Montes de Oca, CJ Shoemaker, M Gucek, RN Cole, KL Wilson PloS one 4 (9), e7050, 2009 | 116 | 2009 |
| Phosphorylation and DNA binding of HJURP determine its centromeric recruitment and function in CenH3CENP-A loading S Müller, RM de Oca, N Lacoste, F Dingli, D Loew, G Almouzni Cell reports 8 (1), 190-203, 2014 | 83 | 2014 |
| The histone chaperone HJURP is a new independent prognostic marker for luminal A breast carcinoma RM de Oca, ZA Gurard-Levin, F Berger, H Rehman, E Martel, A Corpet, ... Molecular oncology 9 (3), 657-674, 2015 | 81 | 2015 |
| Barrier-to-Autointegration Factor influences specific histone modifications R Montes de Oca, PR Andreassen, KL Wilson Nucleus 2 (6), 580-590, 2011 | 81 | 2011 |
| Belantamab Mafodotin (GSK2857916) Drives Immunogenic Cell Death and Immune-mediated Antitumor Responses In Vivo R Montes de Oca, AS Alavi, N Vitali, S Bhattacharya, C Blackwell, K Patel, ... Molecular cancer therapeutics 20 (10), 1941-1955, 2021 | 57 | 2021 |
| Cell cycle dynamics of histone variants at the centromere, a model for chromosomal landmarks E Boyarchuk, RM de Oca, G Almouzni Current opinion in cell biology 23 (3), 266-276, 2011 | 49 | 2011 |
| DREAMM-6: safety, tolerability and clinical activity of belantamab mafodotin (Belamaf) in combination with bortezomib/dexamethasone (BorDex) in relapsed/refractory multiple … R Popat, A Nooka, K Stockerl-Goldstein, R Abonour, R Ramaekers, ... Blood, The Journal of the American Society of Hematology 136 (Supplement 1 …, 2020 | 40 | 2020 |
| The survival gene MED4 explains low penetrance retinoblastoma in patients with large RB1 deletion C Dehainault, A Garancher, L Castéra, N Cassoux, I Aerts, F Doz, ... Human molecular genetics 23 (19), 5243-5250, 2014 | 35 | 2014 |
| Minimal residual disease in myeloma: application for clinical care and new drug registration KC Anderson, D Auclair, SJ Adam, A Agarwal, M Anderson, ... Clinical Cancer Research 27 (19), 5195-5212, 2021 | 34 | 2021 |
| Nuclear membrane protein emerin: roles in gene regulation, actin dynamics and human disease KL Wilson, JM Holaska, RM De Oca, K Tifft, M Zastrow, M Segura‐Totten, ... Nuclear Organization in Development and Disease: Novartis Foundation …, 2005 | 34 | 2005 |
| Functional analysis of patient-derived mutations in the Fanconi anemia gene, FANCG/XRCC9 K Nakanishi, A Moran, T Hays, Y Kuang, E Fox, D Garneau, RM De Oca, ... Experimental hematology 29 (7), 842-849, 2001 | 31 | 2001 |
| Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design AK Nooka, K Weisel, NWCJ van de Donk, D Routledge, PR Otero, K Song, ... Future Oncology 17 (16), 1987-2003, 2021 | 30 | 2021 |
| PF558 THE ANTI‐BCMA ANTIBODY‐DRUG CONJUGATE GSK2857916 DRIVES IMMUNOGENIC CELL DEATH AND IMMUNE‐MEDIATED ANTI‐TUMOR RESPONSES, AND IN COMBINATION WITH AN OX40 AGONIST … R Montes De Oca, S Bhattacharya, N Vitali, K Patel, H Kaczynski, HZ Shi, ... HemaSphere 3, 231, 2019 | 22 | 2019 |
